Galectin Therapeutics Inc. — Form 10-Q Summary
Business Context and Reporting Period
Clinical-stage biopharmaceutical company developing galectin-targeting therapies for fibrotic diseases and cancer. The filing covers the quarter and six months ended June 30, 2014; financial statements are unaudited.
The company has no significant revenue and is focused primarily on GR-MD-02, including Phase 1 development for NASH with advanced liver fibrosis and a Phase 1B melanoma immunotherapy study. GM-CT-01 and additional GR-MD-02 applications remained in earlier-stage development.
Financial Position and Key Metrics
| Metric | Three months ended June 30, 2014 | Six months ended June 30, 2014 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $1.594 million | $4.366 million |
| General and administrative expense | $1.781 million | $3.853 million |
| Total operating expenses | $3.375 million | $8.219 million |
| Net loss | $3.429 million | $8.539 million |
| Net loss applicable to common stockholders | $3.731 million | $9.139 million |
| Loss per common share | $0.17 | $0.42 |
| Net cash used in operating activities | Not separately reported | $6.031 million |
Because the company reported no significant revenue, operating and profit margins are not meaningful. At June 30, 2014, cash and cash equivalents were $34.423 million, compared with $10.489 million at December 31, 2013. Total assets were $34.594 million and total current liabilities were $2.147 million.
The filing does not disclose conventional interest-bearing debt. Capital structure included redeemable convertible preferred stock with carrying values of $6.723 million and stated redemption values of approximately $11.067 million, together with $25.724 million of stockholders’ equity. Common shares outstanding increased to 22.035 million from 18.387 million at year-end 2013.
Cash Flow and Liquidity
- Operating cash use increased to $6.031 million from $4.355 million in the comparable 2013 period.
- Investing cash use was $0.400 million, representing the company’s investment in Galectin Sciences, LLC.
- Financing provided $30.365 million, including $28.178 million of net proceeds from common stock issuance and warrants and $2.187 million from option and warrant exercises.
- Management stated that cash on hand was sufficient to fund currently planned operations through mid-2016, but additional financing or profitable operations will be required thereafter, with no assurance of availability.
Material Changes Versus the Prior Comparable Period
- Second-quarter research and development expense increased 18% to $1.594 million; six-month expense increased 41% to $4.366 million, primarily from Phase 1 clinical activities, manufacturing preparation, and preclinical work for a potential Phase 2 program.
- Second-quarter general and administrative expense increased 49% to $1.781 million; six-month expense increased 45% to $3.853 million, driven principally by higher stock-based compensation and legal costs related to litigation involving former CEO David Platt.
- Six-month net loss increased to $8.539 million from $5.747 million, while net loss applicable to common stockholders declined to $9.139 million from $15.113 million because the 2013 period included an $8.763 million warrant-modification charge.
- Stock-based compensation increased to $2.394 million from $1.467 million for the six months. The company had $5.753 million of unrecognized compensation related to unvested options at June 30, 2014.
- The company issued 2.664 million common shares in January and February 2014 for approximately $28.178 million of net proceeds, substantially increasing liquidity but also diluting existing holders.
- The company formed Galectin Sciences, LLC with SBH Sciences, Inc. and recorded a $0.337 million equity-method loss for the six months, including a $0.200 million noncash charge related to contributed in-process research and development.
Guidance, Outlook, Risks, and Unusual Items
- Management expected to complete the third cohort of the GR-MD-02 Phase 1 trial, with results expected in November 2014, and anticipated initiating a Phase 2 NASH and advanced liver fibrosis trial in early 2015 depending on Phase 1 results. These plans were subject to trial design, recruitment, safety, efficacy, manufacturing, and regulatory uncertainties.
- The company expected continuing losses and rising clinical costs for the foreseeable future. It could not reliably estimate the cost or timing of commercialization or future material cash inflows.
- In June 2014, an arbitrator ruled in favor of former CEO David Platt regarding a disputed $1.0 million separation obligation. The company paid the obligation in July 2014; the amount had been accrued at June 30, 2014.
- On July 30, 2014, the company became aware of a securities class action lawsuit against the company and certain officers. The company disputed the allegations and intended to defend the case.
- Key risks include clinical-trial failure or delay, regulatory approval risk, dependence on additional capital and third-party collaborators, intellectual-property risks, competition, stock-price volatility, and the possibility that products may never generate revenue or profit.
- Management reported effective disclosure controls and procedures as of June 30, 2014 and no material change in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Whether GR-MD-02 clinical-trial results supported the planned Phase 2 program and whether subsequent enrollment and regulatory milestones occurred as projected.
- The company’s actual cash burn after June 30, 2014 and the timing and terms of any subsequent equity financing.
- The status, potential exposure, and accounting treatment of the securities class action lawsuit.
- The final cash impact and any additional obligations associated with the $1.0 million Platt separation payment.
- The fully diluted share count, including 5.451 million outstanding warrants, 3.311 million options, and approximately 2.537 million shares issuable upon preferred-stock conversion.
- Whether the stated cash runway through mid-2016 remained achievable as clinical and research expenditures increased.